JIMT-1 breast cancer xenografts treated with T-DM1 or T-DXd typically expressed less HER2 in immunohistochemistry (usually 1+ on a scale from 0 to 3+) compared to JIMT-1 xenografts treated with PBS (typically 2+; Fig. 5). This evidence concerns the gene ERBB2 and breast carcinoma.